Piper Sandler raised the firm’s price target on Health Catalyst to $17 from $12 and keeps an Overweight rating on the shares. The firm is also raising its 2024 and 2025 adjusted EBITDA estimates following updates from the company, filed via 8K on January 8th. Health Catalyst affirmed that 2023 DOS customer adds and financial results came in at or above the midpoint of guidance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HCAT:
- ‘Profitability Is the Key’: Barclays Says These 3 Health Tech Stocks Are Poised for Growth
- Health Catalyst upgraded to Outperform at Evercore ISI on IT demand inflection
- Barclays starts healthcare technology, distribution with Neutral view
- Health Catalyst upgraded to Outperform from In Line at Evercore ISI
- Health Catalyst initiated with an Overweight at Barclays
